Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-12-12
2006-12-12
Schwadron, Ronald B. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S144100, C424S154100, C424S173100, C424S133100, C424S135100, C424S142100, C530S387300, C530S388150, C530S388730, C530S388220, C530S387100, C530S388750
Reexamination Certificate
active
07147851
ABSTRACT:
The present invention relates to humanized immunoglobulins having binding specificity for α4β7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In one embodiment, the humanized immunoglobulin can compete with murine Act-1 for binding to human α4β7 integrin. In a preferred embodiment, the antigen binding region of the humanized immunoglobulin comprises each of the complementarity determining regions of the light and heavy chains of the murine Act-1 antibody.
REFERENCES:
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5225539 (1993-07-01), Winter
patent: 5258498 (1993-11-01), Huston et al.
patent: 5403919 (1995-04-01), Butcher
patent: 5530101 (1996-06-01), Queen et al.
patent: 5538724 (1996-07-01), Butcher et al.
patent: 5558864 (1996-09-01), Bendig et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5665595 (1997-09-01), Petell et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5840299 (1998-11-01), Bendig et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 5871734 (1999-02-01), Lobb et al.
patent: 5888507 (1999-03-01), Burkly
patent: 5932214 (1999-08-01), Lobb et al.
patent: 6551593 (2003-04-01), Ringler et al.
patent: 0 303 463 (1994-11-01), None
patent: 63 03990 (1994-11-01), None
patent: WO 88/07089 (1988-09-01), None
patent: 90/07321 (1990-07-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 93/02191 (1993-02-01), None
patent: 93/15764 (1993-08-01), None
patent: 94/13312 (1994-06-01), None
patent: 94/16094 (1994-07-01), None
patent: WO 94/17828 (1994-08-01), None
patent: WO 94/29351 (1994-12-01), None
patent: 95/19790 (1995-07-01), None
patent: WO 97/18838 (1997-05-01), None
Rudinger, J. in Peptide Hormones, Parsons, J. A. (Ed.), University Park Press, Baltimore, MD, pp. 1-7, 1976.
Schulz et al., J. Exp. Med., 187:271-275, 1998.
Springer et al., from:“Leucocyte Typing V White Cell Differentiation Antigens, vol. Two”, Oxford University Press, 1995, pp. 1443-1456.
Nieto et al., Clin. Exp. Immunol., 106:170-178, 1996.
Mawhorter et al., J. Immunol., 156:4851-4858, 1996.
Yuan et al., J. Exp. Med., 186:313-323, 1997.
Pritsch et al., J. Clin. Invest., 98:2235-2243, 1996.
J. Immunology 151(1993) Information for Contributors.
Gorman S.D., et al., “Humanisation of Monoclonal Antibodies for Therapy,”Semin. Immunol., 2(6):457-466 (1990).
O'Kennedy R., et al., “Antibody Engineering: An Overview,”Essays Biochem., 26:59-75 (1991).
Winter G., et al., “Humanized Antibodies,”Immunol. Today, 14(6):243-246 (1993).
Feagan, B.G., et al., “An Ascending Dose Trial of a Humanized A4B7Antibody in Ulcerative Colitis (UC),”Gastroenterology 118(4):A874. (Abstract No. 4851).
Feagan, Brian G., et al., “Treatment of Ulcerative Colitis with a Humanized Antibody to the α4β7Integrin,”The New England Journal of Medicine, 352(24):2499-2507 (2005).
Shaw, Denise R., et al., “Mouse/Human Chimeric Antibodies to a Tumor-Associated Antigen: Biologic Activity of the Four Human IgG Subclasses,”Journal of the National Cancer Institute, 80(19):1553-1559 (1988).
Lazarovits, A.I. and Karsh J., “α4β7 integrin in rheumatoid arthritis,” InLeucocyte Typing V—White Cell Differentiation Antigens, S.F. Schlossman et al., eds., (Oxford: Oxford University), pp. 1686, 1687 (1995).
Lazarovits, A.I., et al., “Lymphocyte Activation Antigens—I. A Monoclonal Antibody, Anti-Act I, Defines a New Late Lymphocyte Activation Antigen,”The Journal of Immunology, 133:1857-1862 (1984).
Erle, D.J., et al., “Expression and Function of the MAdCAM-1 Receptor, Integrin α4β7, on Human Leukocytes,”The Journal of Immunology, 153:517-528 (1994).
Postigo, A.A., et al., “α4β7 Integrin Mediates B Cell Binding to Fibronectin and Vascular Cell Adhesion Molecule-1,”The Journal of Immunology, 151:2471-2483 (1993).
Lazarovits, A.I. and Karsh, J., “Differential Expression in Rheumatoid Synovium and Synovial Fluid of α4β7 Integrin—A Novel Receptor for Fibronectin and Vascular Cell Adhesion Molecule-1,”The Journal of Immunology, 151:6482-6489 (1993).
Schweighoffer, T., et al., “Selective Expression of Integrin α4β7 on a Subset of Human CD4+Memory T Cells with Hallmarks of Gut-Trophism,”The Journal of Immunology, 151:717-729 (1993).
Riechmann, L., et al., “Reshaping human antibodies for therapy,”Nature, 332:323-327 (1988).
Bendig, M.M., “Humanization of Rodent Monoclonal Antibodies by CDR Grafting,”METHODS: A Companion to Methods in Enzymology, 8:83-93 (1995).
Page, M.J. and Sydenham, M.A., “High Level Expression of the Humanized Monoclonal Antibody Campath-1H in Chinese Hamster Ovary Cells,”Bio/Technology, 9:64-68 (1991).
Bednarczyk, J.L, et al., “Identification of a Combinatorial Epitope Expressed by the Integrin α4β1 Heterodimer Involved in the Regulation of Cell Adhesion,”J. Biol. Chem., 269:8348-8354 (1994).
Yacyshyn, B.R., et al., “Crohn's Disease, Ulcerative Colitis, and Normal Intestinal Lymphocytes Express Integrins in Dissimilar Patterns,”Gastroenterology, 107:1364-1371 (1994).
Pals, S.T., et al., “Expression of the Mucosal Homing Receptor α4β7 in Malignant Lymphomatous Polyposis of the Intestine,”Gastroenterology, 107:1519-1523 (1994).
Teague, T.K., et al., “Integrin α4β7 Co-Stimulation of Human Peripheral Blood T Cell Proliferation,”Cell Ad. Comm., 2:539-547 (1994).
Tiisala, S., et al., “αEβ7 and α4β7 integrins associated with intraepithelial and mucosal homing, are expressed on macrophages,”Eur. J. Immunol., 25:411-417 (1995).
Wan, H.C., et al., “Expression of α4β7 Integrin on Eosinophils and Modulation of α4-Integrin-Mediated Eosinophil Adhesion via CD4,”Int. Arch. Allergy Immunol., 107:343-344 (1995).
Berg, E.L., et al., “L-Selectin-Mediated Lymphocyte Rolling on MAdCAM-1”,Nature, 366:695-698 (1993).
Berlin, C., et al., “α4 Integrins Mediate Lymphocyte Attachment and Rolling under Physiologic Flow”,Cell, 80:413-422 (1995).
Yang, Y., et al., “Construction and Adhesive Properties of a Soluble MAdCAM-1-Fc Chimera Expressed in a Baculovirus System: Phylogenetic Conservation of Receptor-Ligand Interaction”,Scand. J. Immunol., 42:235-247 (1995).
Hamann, A., et al., “Role of α4-Integrins in Lymphocyte Homing to Mucosal Tissues In Vivo”,J. of Immunology, 152:3282-3293 (1994).
Podolsky, D.K., et al., “Attenuation of Colitis in the Cotton-top Tamarin by Anti-α4 Integrin Monoclonal Antibody”,J. Clin. Invest., 92:372-380 (1993).
Podolsky, D.K., “Inflammatory Bowel Disease (First of Two Parts)”,The New England J. of Med., 325(13):928-937 (1991).
Podolsky, D.K., “Inflammatory Bowel Disease (Second of Two Parts)”,The New England J. of Med., 325(14):1008-1016 (1991).
Springer, T.A., “The Sensation and Regulation of Interactions with the Extracellular Environment: The Cell Biology of Lymphocyte Adhesion Receptors”,Annu. Rev. Cell Biol., 6:359-402 (1990).
Picker, L.J. and Butcher, E.C., “Physiological and Molecular Mechanisms of Lymphocyte Homing”,Annu. Rev. Immunol., 10:561-591 (1992).
Hynes, R.O., “Integrins: Versatility, Modulation, and Signaling in Cell Adhesion”,Cell, 69:11-25 (1992).
Berlin, C., et al., “α4β7 Integrin Mediates Lymphocyte Binding to the Mucosal V
Bendig Mary M.
Jones S. Tarran
Newman Walter
Ponath Paul D.
Ringler Douglas J.
Hamilton Brook Smith & Reynolds P.C.
Millennium Pharmaceuticals Inc.
Schwadron Ronald B.
LandOfFree
Humanized immunoglobulin reactive with α4β7... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized immunoglobulin reactive with α4β7..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized immunoglobulin reactive with α4β7... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3667123